文献速递类风湿关节炎脊柱关节炎

多学科团队干预减少英夫利西单抗转换生物类似药时的反安慰剂效应

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar.
PubMed 文献 · RMD Open · 2021-01-01

该研究在慢性炎症性风湿病患者中,从原研英夫利西单抗转换至生物类似药SB2时实施多学科团队干预。干预包括医护人员培训、护士主导的转换信息沟通和统一术语。34周SB2留存率为91.2%,与历史队列相似但高于3个已发表欧洲队列;12个月留存率为84.5%,因可能反安慰剂效应停药率为6.6%。

要点

  • 多学科团队干预后SB2 34周留存率91.2%,与历史队列相似。
  • 12个月SB2留存率84.5%,因可能反安慰剂效应停药率6.6%。
  • 护士主导的沟通和统一术语可能有助于减少转换时的反安慰剂效应。

核心结论

  • 针对性的沟通干预以护士为主导,在非医疗原因从原研英夫利西单抗转换至SB2时减少了反安慰剂效应。
  • SB2留存率与历史队列相似,且高于3个已发表的欧洲队列。

研究设计与样本

  • 干预方案由医护人员和一名患者代表共同构建,基于系统综述和半定向访谈。
  • 纳入2018年3月起所有从原研英夫利西单抗转换至SB2的慢性炎症性风湿病患者45例(类风湿关节炎17例,脊柱关节炎28例)。
  • 主要结局为34周SB2留存率,次要结局包括12个月留存率、因可能反安慰剂效应停药率,并与历史队列及6个已发表欧洲队列比较。

主要发现

  • 34周SB2留存率为91.2%,与历史队列留存率相似(p=0.41),但高于3个欧洲队列留存率(p<0.05)。
  • 12个月SB2留存率为84.5%,历史队列为88.4%(p=0.52)。
  • 12个月时因可能反安慰剂效应导致的SB2停药率为6.6%。

临床怎么用

  • 在从原研英夫利西单抗转换至生物类似药时,可考虑采用医护人员培训、护士主导的信息沟通和统一术语的多学科团队干预。
  • 该干预方法可能有助于改善未来生物类似药转换的结局。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate an intervention to reduce the nocebo effect (NE) when switching from the originator infliximab (OI) to the infliximab biosimilar SB2 in chronic inflammatory rheumatic disease (CIRD). METHODS: An intervention was built with healthcare professionals (HPs) and a patient representative, based on a systematic review of interventions reducing the NE in musculoskeletal diseases and semi-directed questioning of five patients. Our strategy consisted of training HPs, switch information given by the nurses, a consistent vocabulary. All CIRD patients switched from OI to SB2 were included for the intervention. The primary outcome was the SB2 retention rate (RR) at 34 weeks. Secondary outcomes were the SB2 RR at 12 months, discontinuation rates due to a possible NE and comparison with a historical cohort of CIRD patients receiving the OI and 6 published European cohorts. RESULTS: 45 patients were included from March 2018 (rheumatoid arthritis, n=17, spondylarthritis, n=28). After 34 weeks, the SB2 RR was 91.2%, similar to the historical cohort RR (p=0.41) but higher than the 3 European cohort RRs (p<0.05). At 12 months, the SB2 RR was 84.5% vs 88.4% for the historical cohort (p=0.52). SB2 discontinuation due to a possible NE was 6.6% after 12 months. CONCLUSIONS: A tailored communication with a prominent role of nurses reduced the NE in non-medical switches from the OI to SB2 as compared to published results. The RR was similar to the historical cohort RR. The methodology used to construct this intervention may help improve the outcomes of switches with upcoming biosimilars.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Petit J, Antignac M, Poilverd RM, et al. Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar. RMD Open. 2021. PMID: 33495387. doi:10.1136/rmdopen-2020-001396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。